WO2000050019A3 - VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN - Google Patents

VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN Download PDF

Info

Publication number
WO2000050019A3
WO2000050019A3 PCT/EP2000/000323 EP0000323W WO0050019A3 WO 2000050019 A3 WO2000050019 A3 WO 2000050019A3 EP 0000323 W EP0000323 W EP 0000323W WO 0050019 A3 WO0050019 A3 WO 0050019A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
activation
humans
animals
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/000323
Other languages
English (en)
French (fr)
Other versions
WO2000050019A2 (de
Inventor
Gerd Geisslinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PAZ ARZNEIMITTEL-ENTWICKLUNGSGESELLSCHAFT MBH
PAZ ARZNEIMITTELENTWICKLUNG
Original Assignee
PAZ ARZNEIMITTEL-ENTWICKLUNGSGESELLSCHAFT MBH
PAZ ARZNEIMITTELENTWICKLUNG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7898653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000050019(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PAZ ARZNEIMITTEL-ENTWICKLUNGSGESELLSCHAFT MBH, PAZ ARZNEIMITTELENTWICKLUNG filed Critical PAZ ARZNEIMITTEL-ENTWICKLUNGSGESELLSCHAFT MBH
Priority to DK00904922T priority Critical patent/DK1154766T3/da
Priority to CA002362888A priority patent/CA2362888C/en
Priority to DE50013934T priority patent/DE50013934D1/de
Priority to JP2000600631A priority patent/JP2002537325A/ja
Priority to EP00904922A priority patent/EP1154766B1/de
Publication of WO2000050019A2 publication Critical patent/WO2000050019A2/de
Publication of WO2000050019A3 publication Critical patent/WO2000050019A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von R-Enantiomeren von Arylpropionsäuren oder Arylpropionsäurederivaten, zur Herstellung von Arzneimitteln, welche die NF-λB-Aktivierungskaskade hemmen und damit zur Behandlung von Erkrankungen geeignet sind, welche durch die Hemmung der NF-λB-Bildung therapeutisch positiv beeinflusst werden können.
PCT/EP2000/000323 1999-02-24 2000-01-17 VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN Ceased WO2000050019A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK00904922T DK1154766T3 (da) 1999-02-24 2000-01-17 Anvendelse af R-arylpropionsyre til fremstilling af lægemidler til behandling af sygdomme hos mennesker og dyr, hvor sygdommene kan påvirkes terapeutisk ved inhibering af aktiveringen af NF-kappa B
CA002362888A CA2362888C (en) 1999-02-24 2000-01-17 Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kb
DE50013934T DE50013934D1 (de) 1999-02-24 2000-01-17 Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
JP2000600631A JP2002537325A (ja) 1999-02-24 2000-01-17 ＮＦ−κＢの活性化を阻害することにより治療上の影響を与えることができる、ヒトおよび動物における病気を治療するための医薬を製造するためのＲ−アリールプロピオン酸の使用
EP00904922A EP1154766B1 (de) 1999-02-24 2000-01-17 Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19907895.5 1999-02-24
DE19907895A DE19907895A1 (de) 1999-02-24 1999-02-24 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können

Publications (2)

Publication Number Publication Date
WO2000050019A2 WO2000050019A2 (de) 2000-08-31
WO2000050019A3 true WO2000050019A3 (de) 2000-12-14

Family

ID=7898653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000323 Ceased WO2000050019A2 (de) 1999-02-24 2000-01-17 VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN

Country Status (11)

Country Link
EP (1) EP1154766B1 (de)
JP (1) JP2002537325A (de)
AT (1) ATE350027T1 (de)
CA (1) CA2362888C (de)
CY (1) CY1108004T1 (de)
DE (2) DE19907895A1 (de)
DK (1) DK1154766T3 (de)
ES (1) ES2280196T3 (de)
PT (1) PT1154766E (de)
RU (1) RU2250103C2 (de)
WO (1) WO2000050019A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20030312A1 (it) * 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
SI2387391T1 (sl) 2009-07-24 2017-04-26 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Postopek za pripravo tekočega sestavka, ki se nanaša na kožo v obliki pene, in sestavka, ki se lahko nanaša topično
GB2485169A (en) * 2010-11-03 2012-05-09 Univ Jw Goethe Frankfurt Main (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP2468270A1 (de) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-Fluor-4-phenylphenyl)propionsäure zur Behandlung von Hauterkrankungen
RU2457840C1 (ru) * 2011-03-09 2012-08-10 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Средство, воздействующее на активность некоторых ядерных факторов транскрипции
WO2014007779A1 (en) 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
WO2014007780A1 (en) 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
RU2675693C1 (ru) * 2017-11-16 2018-12-24 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ ингибирования нуклеарного фактора каппа В с использованием 5-гидроксиникотината калия в культуре клеток

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009603A2 (en) * 1996-09-06 1998-03-12 Loma Linda University Medical Center Compositions including r-nsaids and therapeutic and prophylactic methods employing said compositions
WO1998047502A1 (de) * 1997-04-21 1998-10-29 Paz Arzneimittel-Entwicklungsgesellschaft Mbh IBUPROFENTHIOESTER ALS HEMMER DER Nf-λB ABHÄNGIGEN BILDUNG VON MEDIATOREN VON ENTZÜNDUNG UND SCHMERZ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
ATE353010T1 (de) * 1998-09-03 2007-02-15 Univ Loma Linda Med Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009603A2 (en) * 1996-09-06 1998-03-12 Loma Linda University Medical Center Compositions including r-nsaids and therapeutic and prophylactic methods employing said compositions
WO1998047502A1 (de) * 1997-04-21 1998-10-29 Paz Arzneimittel-Entwicklungsgesellschaft Mbh IBUPROFENTHIOESTER ALS HEMMER DER Nf-λB ABHÄNGIGEN BILDUNG VON MEDIATOREN VON ENTZÜNDUNG UND SCHMERZ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
N. SCEUREN: "Modulation of transcription factors by nonsteroidal anti-inflammatory drugs", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 354, no. 4 suppl. 1, 1996, pages R5, XP000938437 *
N. SCEUREN: "Weak inhibitors of cyclooxygenases may exert their antinociceptive effect by modulation of transcription factors", ADV. EXP. MED. BIOL., vol. 433, 1997, pages 51 - 54, XP000938438 *
N. SCHEUREN: "Enantiomers of the nonsteroidal anti-inflammatory drug ibuprofen are potent and specific inhibitors of transcription factor NF-kappa,beta", NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL., vol. 357, no. 4 supl., 1998, pages R16, XP000938436 *
N. SCHEUREN: "Modulation of transcription factor NF-kapa,beta by enantiomers of the nonsteroidal drug ibuprofen", BR. J. PHARMACOL., vol. 123, no. 4, 1998, pages 645 - 652, XP000938435 *

Also Published As

Publication number Publication date
CA2362888A1 (en) 2000-08-31
CY1108004T1 (el) 2013-09-04
JP2002537325A (ja) 2002-11-05
ES2280196T3 (es) 2007-09-16
DE50013934D1 (de) 2007-02-15
DE19907895A1 (de) 2000-11-16
RU2250103C2 (ru) 2005-04-20
DK1154766T3 (da) 2007-05-14
PT1154766E (pt) 2007-03-30
EP1154766B1 (de) 2007-01-03
ATE350027T1 (de) 2007-01-15
EP1154766A2 (de) 2001-11-21
WO2000050019A2 (de) 2000-08-31
CA2362888C (en) 2009-02-24

Similar Documents

Publication Publication Date Title
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
WO2002053141A3 (en) Inhibition of angiogenesis by nucleic acids
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2000050019A3 (de) VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN
CA2168963A1 (en) Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
WO2000027819A3 (de) Anthranilsäureamide und deren verwendung als arzneimittel
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2000020612A3 (en) Therapeutically active proteins in plants
WO2004005286A3 (en) Viral inhibitors
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO1998025930A3 (en) Use of bi- and tricyclic pyridone derivatives against alzheimer's disease
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
WO2003037323A3 (en) Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
WO1994020062A3 (en) Balanoids as protein kinase c inhibitors
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
WO2001051044A3 (en) Substances for use in treating psoriasis
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
PT1206444E (pt) Compostos que inibem a actividade da triptase
TW200510308A (en) Isophthalic acid derivatives
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
BR0213479A (pt) Utilização do irbesartan para a preparação de medicamentos úteis para a prevenção ou o tratamento da hipertensão pulmonar
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2003007930A3 (en) Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000904922

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2362888

Country of ref document: CA

Ref country code: CA

Ref document number: 2362888

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 600631

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09914270

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000904922

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000904922

Country of ref document: EP